These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 24929754)
1. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy. Newman H; Breunig L; van Zyl G; Stich A; Preiser W J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754 [TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
3. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793 [TBL] [Abstract][Full Text] [Related]
4. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120 [TBL] [Abstract][Full Text] [Related]
5. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391 [TBL] [Abstract][Full Text] [Related]
6. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy. Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611 [TBL] [Abstract][Full Text] [Related]
7. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa. Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647 [TBL] [Abstract][Full Text] [Related]
8. Pooled HIV-1 RNA viral load testing for detection of antiretroviral treatment failure in Kenyan children. Chohan BH; Tapia K; Merkel M; Kariuki AC; Khasimwa B; Olago A; Gichohi R; Obimbo EM; Wamalwa DC J Acquir Immune Defic Syndr; 2013 Jul; 63(3):e87-93. PubMed ID: 23542638 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol. Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150 [TBL] [Abstract][Full Text] [Related]
10. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398 [TBL] [Abstract][Full Text] [Related]
11. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings. Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J; HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882 [TBL] [Abstract][Full Text] [Related]
13. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R; Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603 [TBL] [Abstract][Full Text] [Related]
14. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico. Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822 [TBL] [Abstract][Full Text] [Related]
15. Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in Mozambique. Tilghman M; Tsai D; Buene TP; Tomas M; Amade S; Gehlbach D; Chang S; Ignacio C; Caballero G; Espitia S; May S; Noormahomed EV; Smith DM J Acquir Immune Defic Syndr; 2015 Nov; 70(3):256-61. PubMed ID: 26135327 [TBL] [Abstract][Full Text] [Related]
16. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria. Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614 [TBL] [Abstract][Full Text] [Related]
17. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W; Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461 [TBL] [Abstract][Full Text] [Related]
18. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
19. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D; Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439 [TBL] [Abstract][Full Text] [Related]
20. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa. Nwobegahay J; Selabe G; Ndjeka NO; Manhaeve C; Bessong PO J Med Virol; 2012 Dec; 84(12):1839-43. PubMed ID: 23080485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]